Skip to main content
Top
Published in: BMC Public Health 1/2012

Open Access 01-12-2012 | Research article

The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population

Authors: Xia Sheng, Michael J Murphy, Thomas M MacDonald, Li Wei

Published in: BMC Public Health | Issue 1/2012

Login to get access

Abstract

Background

Total cholesterol (TC) concentration is the most commonly used measure of statin efficacy in the UK. This study aimed to evaluate the effectiveness of statins in lowering TC, cardiovascular events (CV) and mortality five common chronic diseases (chronic obstructive pulmonary disease (COPD), osteoarthritis (OA), rheumatoid arthritis (RA), chronic kidney disease (CKD), and diabetes mellitus (DM)) and to compare effectiveness with the rest of the population not recorded as having these diseases.

Methods

A population-based cohort study was conducted in Tayside population who had at least two TC measurements between 1993 and 2007. There were 12,140 patients with chronic diseases and 9,481 patients in the rest of the population not recorded as having these chronic diseases. The main outcomes were TC change from baseline, CV events and all-cause mortality.

Results

Statin-associated TC reductions varied from 15% to 28% with baseline value of between 5.1 and 5.9 mmol/L in the primary prevention (PP) and from 7% to 23% with baseline value of 4.5 to 5.2 mmol/L in the secondary prevention (SP) among chronic diseases patients. In the rest of the population, TC reductions with statins were 31% in PP and 28% in SP with baselines of 6.3 mmol/L and 5.3 mmol/L, respectively (test of heterogeneity with chronic disease groups: p < 0.001). A notional reduction of 0.5 mmol/L in TC predicted variable reductions in incident CV events of 30% in RA, 19% in CKD, and 20% in DM, and recurrent CV events by 62% in COPD, 16% in CKD, and 19% in DM. The corresponding figures for the rest of population were 12% for incident CV events and 17% for the recurrent CV events, respectively. Risk reductions for all-cause mortality varied from 20% to 36% in PP and from 18% to 40% in SP, except in OA or RA patients in the chronic diseases and 11% in PP and 16% in the rest of population (test of heterogeneity: p > 0.05).

Conclusions

The effectiveness of statins in common chronic diseases varied. With the exception of diabetes, statins tends to be less effective in patients with the chronic diseases compared with the rest of the study population. Changes in TC with statins appear not to correlate well with the changes in cardiovascular events and all-cause mortality.
Appendix
Available only for authorised users
Literature
1.
go back to reference Yach D, Hawkes C, Gould CL, Hofman KJ: The global burden of chronic diseases: Overcoming impediments to prevention and control. JAMA. 2004, 291: 2616-2622. 10.1001/jama.291.21.2616.CrossRefPubMed Yach D, Hawkes C, Gould CL, Hofman KJ: The global burden of chronic diseases: Overcoming impediments to prevention and control. JAMA. 2004, 291: 2616-2622. 10.1001/jama.291.21.2616.CrossRefPubMed
2.
go back to reference Beaglehole R, Yach D: Globalisation and the prevention and control of non-communicable disease: The neglected chronic diseases of adults. Lancet. 2003, 362: 903-908. 10.1016/S0140-6736(03)14335-8.CrossRefPubMed Beaglehole R, Yach D: Globalisation and the prevention and control of non-communicable disease: The neglected chronic diseases of adults. Lancet. 2003, 362: 903-908. 10.1016/S0140-6736(03)14335-8.CrossRefPubMed
3.
go back to reference Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM: Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006, 28: 523-532. 10.1183/09031936.06.00124605.CrossRefPubMed Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM: Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006, 28: 523-532. 10.1183/09031936.06.00124605.CrossRefPubMed
4.
5.
go back to reference Murray CJL, Lopez AD: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997, 349: 1498-1504. 10.1016/S0140-6736(96)07492-2.CrossRefPubMed Murray CJL, Lopez AD: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997, 349: 1498-1504. 10.1016/S0140-6736(96)07492-2.CrossRefPubMed
6.
go back to reference Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for 2000 and projections for 2030. Diabetes Care. 2004, 27: 1047-1053. 10.2337/diacare.27.5.1047.CrossRefPubMed Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for 2000 and projections for 2030. Diabetes Care. 2004, 27: 1047-1053. 10.2337/diacare.27.5.1047.CrossRefPubMed
7.
go back to reference Couser WG, Shah S, Kopple J, Beerkens P, Wilson A, Feehally J, Reiser T, Riella M: A call to action on World Kidney Day, 8 March 2007. Kidney Int. 2007, 71: 369-370. 10.1038/sj.ki.5002144.CrossRefPubMed Couser WG, Shah S, Kopple J, Beerkens P, Wilson A, Feehally J, Reiser T, Riella M: A call to action on World Kidney Day, 8 March 2007. Kidney Int. 2007, 71: 369-370. 10.1038/sj.ki.5002144.CrossRefPubMed
8.
go back to reference Zhang QL, Rothenbacher D: Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Publ Health. 2008, 8: 117-10.1186/1471-2458-8-117.CrossRef Zhang QL, Rothenbacher D: Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Publ Health. 2008, 8: 117-10.1186/1471-2458-8-117.CrossRef
11.
go back to reference Brion PH, Kalunian KC: Oxford textbook of medicine. Section 18.8. Osteoarthritis. Edited by: Warrell DA, Cox TM, Firth JD, Benz EJ Jr. 2003, Oxford University, Oxford, 4 Brion PH, Kalunian KC: Oxford textbook of medicine. Section 18.8. Osteoarthritis. Edited by: Warrell DA, Cox TM, Firth JD, Benz EJ Jr. 2003, Oxford University, Oxford, 4
12.
go back to reference Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, Sowers JR: Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999, 100: 1134-1146. 10.1161/01.CIR.100.10.1134.CrossRefPubMed Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, Sowers JR: Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999, 100: 1134-1146. 10.1161/01.CIR.100.10.1134.CrossRefPubMed
13.
go back to reference Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998, 339: 229-234. 10.1056/NEJM199807233390404.CrossRefPubMed Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998, 339: 229-234. 10.1056/NEJM199807233390404.CrossRefPubMed
14.
go back to reference Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003, 108: 2154-2169. 10.1161/01.CIR.0000095676.90936.80.CrossRefPubMed Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003, 108: 2154-2169. 10.1161/01.CIR.0000095676.90936.80.CrossRefPubMed
15.
go back to reference Perazella MA, Khan S: Increased mortality in chronic kidney disease: a call to action. Am J Med Sci. 2006, 331: 150-153. 10.1097/00000441-200603000-00007.CrossRefPubMed Perazella MA, Khan S: Increased mortality in chronic kidney disease: a call to action. Am J Med Sci. 2006, 331: 150-153. 10.1097/00000441-200603000-00007.CrossRefPubMed
16.
go back to reference Sidney S, Sorel M, Quesenberry CP, DeLuise C, Lanes S, Eisner MD: COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005, 128: 2068-2075. 10.1378/chest.128.4.2068.CrossRefPubMed Sidney S, Sorel M, Quesenberry CP, DeLuise C, Lanes S, Eisner MD: COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005, 128: 2068-2075. 10.1378/chest.128.4.2068.CrossRefPubMed
17.
go back to reference Mannino DM, Thorn D, Swensen A, Holguin F: Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008, 32: 962-969. 10.1183/09031936.00012408.CrossRefPubMed Mannino DM, Thorn D, Swensen A, Holguin F: Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008, 32: 962-969. 10.1183/09031936.00012408.CrossRefPubMed
18.
go back to reference Wallberg-Jonsson S, Ohman ML, Dahlqvist SR: Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol. 1997, 24: 445-451.PubMed Wallberg-Jonsson S, Ohman ML, Dahlqvist SR: Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol. 1997, 24: 445-451.PubMed
19.
go back to reference Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE: Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005, 52: 722-732. 10.1002/art.20878.CrossRefPubMed Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE: Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005, 52: 722-732. 10.1002/art.20878.CrossRefPubMed
20.
go back to reference Sin DD, Anthonisen NR, Soriano JB, Agusti AG: Mortality in COPD: Role of comorbidities. Eur Respir J. 2006, 28: 1245-1257. 10.1183/09031936.00133805.CrossRefPubMed Sin DD, Anthonisen NR, Soriano JB, Agusti AG: Mortality in COPD: Role of comorbidities. Eur Respir J. 2006, 28: 1245-1257. 10.1183/09031936.00133805.CrossRefPubMed
21.
go back to reference Yerram P, Karuparthi PR, Hesemann L, Horst J, Whaley-Connell A: Chronic kidney disease and cardiovascular risk. J Am Soc Hypertens. 2007, 1: 178-184. 10.1016/j.jash.2007.01.010.CrossRefPubMed Yerram P, Karuparthi PR, Hesemann L, Horst J, Whaley-Connell A: Chronic kidney disease and cardiovascular risk. J Am Soc Hypertens. 2007, 1: 178-184. 10.1016/j.jash.2007.01.010.CrossRefPubMed
22.
go back to reference Haffner SM: Management of dyslipidemia in adults with diabetes. American Diabetes Association. Diabetes Care. 1998, 21: 179-182.CrossRef Haffner SM: Management of dyslipidemia in adults with diabetes. American Diabetes Association. Diabetes Care. 1998, 21: 179-182.CrossRef
23.
go back to reference Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, Bellanuova I, Malatino LS, Soldarini A: Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int. 2002, 61: 609-614. 10.1046/j.1523-1755.2002.00144.x.CrossRefPubMed Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, Bellanuova I, Malatino LS, Soldarini A: Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int. 2002, 61: 609-614. 10.1046/j.1523-1755.2002.00144.x.CrossRefPubMed
24.
go back to reference Hunninghake DB: Cardiovascular disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005, 2: 44-49. 10.1513/pats.200410-050SF.CrossRefPubMed Hunninghake DB: Cardiovascular disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005, 2: 44-49. 10.1513/pats.200410-050SF.CrossRefPubMed
25.
go back to reference Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R: Cholesterol Treatment Trialists’ (CTT) collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010, 376: 1670-1681. 10.1016/S0140-6736(10)61350-5.CrossRefPubMed Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R: Cholesterol Treatment Trialists’ (CTT) collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010, 376: 1670-1681. 10.1016/S0140-6736(10)61350-5.CrossRefPubMed
26.
go back to reference Murphy MJ, Wei L, Watson AD, MacDonald TM: 'Real-life' reduction in cholesterol with statins, 1993 to 2002. Br J Clin Pharmacol. 2008, 65: 587-592. 10.1111/j.1365-2125.2007.03066.x.CrossRefPubMedPubMedCentral Murphy MJ, Wei L, Watson AD, MacDonald TM: 'Real-life' reduction in cholesterol with statins, 1993 to 2002. Br J Clin Pharmacol. 2008, 65: 587-592. 10.1111/j.1365-2125.2007.03066.x.CrossRefPubMedPubMedCentral
27.
go back to reference Sheng X, Wei L, Murphy MJ, MacDonald TM: Statins and total (not LDL) cholesterol concentration and outcome of myocardial infarction: results from a meta-analysis and an observational study. Eur J Clin Pharmacol. 2009, 65: 1071-1080. 10.1007/s00228-009-0720-x.CrossRefPubMed Sheng X, Wei L, Murphy MJ, MacDonald TM: Statins and total (not LDL) cholesterol concentration and outcome of myocardial infarction: results from a meta-analysis and an observational study. Eur J Clin Pharmacol. 2009, 65: 1071-1080. 10.1007/s00228-009-0720-x.CrossRefPubMed
29.
go back to reference Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 2002, 21 (11): 1539-1558. 10.1002/sim.1186.CrossRefPubMed Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 2002, 21 (11): 1539-1558. 10.1002/sim.1186.CrossRefPubMed
30.
go back to reference Friedwald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18: 499-502. Friedwald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18: 499-502.
31.
go back to reference Ferrara A, Barrett-Connor E, Shan J: Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. Circulation. 1997, 96: 37-43. 10.1161/01.CIR.96.1.37.CrossRefPubMed Ferrara A, Barrett-Connor E, Shan J: Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. Circulation. 1997, 96: 37-43. 10.1161/01.CIR.96.1.37.CrossRefPubMed
32.
go back to reference Abbott RD, Yano K, Hakim AA, Burchfiel CM, Sharp DS, Rodriguez BL, Curb JD: Changes in total and high-density lipoprotein cholesterol over 10- and 20-year periods (the Honolulu Heart Program). Am J Cardiol. 1998, 82: 172-178. 10.1016/S0002-9149(98)00310-5.CrossRefPubMed Abbott RD, Yano K, Hakim AA, Burchfiel CM, Sharp DS, Rodriguez BL, Curb JD: Changes in total and high-density lipoprotein cholesterol over 10- and 20-year periods (the Honolulu Heart Program). Am J Cardiol. 1998, 82: 172-178. 10.1016/S0002-9149(98)00310-5.CrossRefPubMed
33.
go back to reference Manolio TA, Ettinger WH, Tracy RP, Kuller LH, Borhani NO, Lynch JC, Fried LP: Epidemiology of low cholesterol levels in older adults. The Cardiovascular Health Study. Circulation. 1993, 87: 728-737. 10.1161/01.CIR.87.3.728.CrossRefPubMed Manolio TA, Ettinger WH, Tracy RP, Kuller LH, Borhani NO, Lynch JC, Fried LP: Epidemiology of low cholesterol levels in older adults. The Cardiovascular Health Study. Circulation. 1993, 87: 728-737. 10.1161/01.CIR.87.3.728.CrossRefPubMed
34.
go back to reference Schaefer EJ, Moussa PB, Wilson PW, McGee D, Dallal G, Castelli WP: Plasma lipoproteins in healthy octogenarians: Lack of reduced high density lipoprotein cholesterol levels: Results from the Framingham Heart Study. Metabolism. 1989, 38: 293-296. 10.1016/0026-0495(89)90113-3.CrossRefPubMed Schaefer EJ, Moussa PB, Wilson PW, McGee D, Dallal G, Castelli WP: Plasma lipoproteins in healthy octogenarians: Lack of reduced high density lipoprotein cholesterol levels: Results from the Framingham Heart Study. Metabolism. 1989, 38: 293-296. 10.1016/0026-0495(89)90113-3.CrossRefPubMed
35.
go back to reference Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD: Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003, 42: 864-881. 10.1016/j.ajkd.2003.07.016.CrossRefPubMed Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD: Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003, 42: 864-881. 10.1016/j.ajkd.2003.07.016.CrossRefPubMed
36.
go back to reference Iribarren C, Jacobs DR, Sidney S, Claxton AJ, Gross MD, Sadler M, Blackburn H: Serum total cholesterol and risk of hospitalization, and death from respiratory disease. Int J Epidemiol. 1997, 26: 1191-1202. 10.1093/ije/26.6.1191.CrossRefPubMed Iribarren C, Jacobs DR, Sidney S, Claxton AJ, Gross MD, Sadler M, Blackburn H: Serum total cholesterol and risk of hospitalization, and death from respiratory disease. Int J Epidemiol. 1997, 26: 1191-1202. 10.1093/ije/26.6.1191.CrossRefPubMed
37.
go back to reference Rantapää-Dahlqvist S, Wållberg-Jonsson S, Dahlén G: Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis. 1991, 50: 366-368. 10.1136/ard.50.6.366.CrossRefPubMedPubMedCentral Rantapää-Dahlqvist S, Wållberg-Jonsson S, Dahlén G: Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis. 1991, 50: 366-368. 10.1136/ard.50.6.366.CrossRefPubMedPubMedCentral
38.
go back to reference Dursunoğlu D, Evrengül H, Polat B, Tanriverdi H, Cobankara V, Kaftan A, Kiliç M: Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int. 2005, 25: 241-245. 10.1007/s00296-004-0438-0.CrossRefPubMed Dursunoğlu D, Evrengül H, Polat B, Tanriverdi H, Cobankara V, Kaftan A, Kiliç M: Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int. 2005, 25: 241-245. 10.1007/s00296-004-0438-0.CrossRefPubMed
39.
go back to reference Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA. 2004, 291: 451-459. 10.1001/jama.291.4.451.CrossRefPubMed Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA. 2004, 291: 451-459. 10.1001/jama.291.4.451.CrossRefPubMed
40.
go back to reference Anderson KM, Castelli WP, Levy D: Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987, 257: 2176-2180. 10.1001/jama.1987.03390160062027.CrossRefPubMed Anderson KM, Castelli WP, Levy D: Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987, 257: 2176-2180. 10.1001/jama.1987.03390160062027.CrossRefPubMed
41.
42.
go back to reference Weiss R, Harder M, Rowe J: The relationship between nonfasting and fasting lipid measurments in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3methyglutaryl-coenzyme A reductase inhibitors. Clin Ther. 2003, 25: 1490-1497. 10.1016/S0149-2918(03)80134-0.CrossRefPubMed Weiss R, Harder M, Rowe J: The relationship between nonfasting and fasting lipid measurments in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3methyglutaryl-coenzyme A reductase inhibitors. Clin Ther. 2003, 25: 1490-1497. 10.1016/S0149-2918(03)80134-0.CrossRefPubMed
43.
go back to reference American Diabetes Association: Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998, 21 (1): 179-182.CrossRef American Diabetes Association: Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998, 21 (1): 179-182.CrossRef
44.
go back to reference Harper CR, Jacobson TA: Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008, 51 (25): 2375-2384. 10.1016/j.jacc.2008.03.025.CrossRefPubMed Harper CR, Jacobson TA: Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008, 51 (25): 2375-2384. 10.1016/j.jacc.2008.03.025.CrossRefPubMed
45.
go back to reference Kaysen GA: Dyslipidemia in chronic kidney disease: causes and consequences. Kidney Int. 2006, 70: 555-558.CrossRef Kaysen GA: Dyslipidemia in chronic kidney disease: causes and consequences. Kidney Int. 2006, 70: 555-558.CrossRef
46.
go back to reference Walsh GM: Statins as emerging treatments for asthma and chronic obstructive pulmonary disease. Expert Rev Respir Med. 2008, 2 (3): 329-335. 10.1586/17476348.2.3.329.CrossRefPubMed Walsh GM: Statins as emerging treatments for asthma and chronic obstructive pulmonary disease. Expert Rev Respir Med. 2008, 2 (3): 329-335. 10.1586/17476348.2.3.329.CrossRefPubMed
47.
go back to reference McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N: Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004, 363 (9426): 2015-2021. 10.1016/S0140-6736(04)16449-0.CrossRefPubMed McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N: Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004, 363 (9426): 2015-2021. 10.1016/S0140-6736(04)16449-0.CrossRefPubMed
48.
go back to reference Paraskevas KI: Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol. 2008, 27 (3): 281-287. 10.1007/s10067-007-0806-8.CrossRefPubMed Paraskevas KI: Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol. 2008, 27 (3): 281-287. 10.1007/s10067-007-0806-8.CrossRefPubMed
49.
go back to reference Lee TM, Lin MS, Change NC: Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol. 2008, 101: 530-535. 10.1016/j.amjcard.2007.09.102.CrossRefPubMed Lee TM, Lin MS, Change NC: Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol. 2008, 101: 530-535. 10.1016/j.amjcard.2007.09.102.CrossRefPubMed
50.
go back to reference van Gestel YR, Hoeks SE, Sin DD, Simsek C, Welten GM, Schouten O, Stam H, Mertens FW, van Domburg RT, Poldermans D: Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol. 2008, 102 (2): 192-196. 10.1016/j.amjcard.2008.03.038.CrossRefPubMed van Gestel YR, Hoeks SE, Sin DD, Simsek C, Welten GM, Schouten O, Stam H, Mertens FW, van Domburg RT, Poldermans D: Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol. 2008, 102 (2): 192-196. 10.1016/j.amjcard.2008.03.038.CrossRefPubMed
51.
go back to reference Mäki-Petäjä KM, Booth AD, Hall FC, Wallace SM, Brown J, McEniery CM, Wilkinson IB: Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol. 2007, 50 (9): 852-858. 10.1016/j.jacc.2007.04.076.CrossRefPubMed Mäki-Petäjä KM, Booth AD, Hall FC, Wallace SM, Brown J, McEniery CM, Wilkinson IB: Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol. 2007, 50 (9): 852-858. 10.1016/j.jacc.2007.04.076.CrossRefPubMed
52.
go back to reference Hermann F, Forster A, Chenevard R, et al: Simvastatin improves endothelial function in patients with Rheumatoid arthritis. J Am Coll Cardiol. 2005, 45: 461-464. 10.1016/j.jacc.2004.11.006.CrossRefPubMed Hermann F, Forster A, Chenevard R, et al: Simvastatin improves endothelial function in patients with Rheumatoid arthritis. J Am Coll Cardiol. 2005, 45: 461-464. 10.1016/j.jacc.2004.11.006.CrossRefPubMed
53.
go back to reference Tikiz C, Utuk O, Pirildar T, Bayturan O, Bayindir P, Taneli F, Tikiz H, Tuzun C: Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol. 2005, 32 (11): 2095-2101.PubMed Tikiz C, Utuk O, Pirildar T, Bayturan O, Bayindir P, Taneli F, Tikiz H, Tuzun C: Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol. 2005, 32 (11): 2095-2101.PubMed
54.
go back to reference Van Doornum S, McColl G, Wicks IP: Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis. 2004, 63 (12): 1571-1575. 10.1136/ard.2003.018333.CrossRefPubMedPubMedCentral Van Doornum S, McColl G, Wicks IP: Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis. 2004, 63 (12): 1571-1575. 10.1136/ard.2003.018333.CrossRefPubMedPubMedCentral
55.
go back to reference Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM, Paulus HE, Park GS, Gong T, Ansell BJ: Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol. 2007, 34 (7): 1459-1464.PubMed Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM, Paulus HE, Park GS, Gong T, Ansell BJ: Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol. 2007, 34 (7): 1459-1464.PubMed
56.
go back to reference Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC: Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008, 336 (7645): 645-651. 10.1136/bmj.39472.580984.AE.CrossRefPubMedPubMedCentral Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC: Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008, 336 (7645): 645-651. 10.1136/bmj.39472.580984.AE.CrossRefPubMedPubMedCentral
57.
go back to reference Costa J, Borges M, David C, Vaz Carneiro A: Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006, 332 (7550): 1115-1124. 10.1136/bmj.38793.468449.AE.CrossRefPubMedPubMedCentral Costa J, Borges M, David C, Vaz Carneiro A: Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006, 332 (7550): 1115-1124. 10.1136/bmj.38793.468449.AE.CrossRefPubMedPubMedCentral
Metadata
Title
The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population
Authors
Xia Sheng
Michael J Murphy
Thomas M MacDonald
Li Wei
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2012
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-12-712

Other articles of this Issue 1/2012

BMC Public Health 1/2012 Go to the issue